-
Mashup Score: 10Targeting Senescence for Next-Generation Cancer Treatments - 4 day(s) ago
Summary:. Cellular senescence has paradoxical effects on cancer emergence, progression, and therapeutic response. We herein identify four lessons that emerged from studying senescence interaction with cancer and emphasize four bottlenecks in the therapeutic manipulation of cellular senescence to prevent or cure cancer.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 11
Summary:. Beyond lipid membrane compartments, cells including cancer cells utilize various membraneless compartments, often termed biomolecular condensates, to regulate or organize key cellular processes underlying physiologic or pathologic phenotypes. In this commentary, the emergence of biomolecular condensation in cancer biology is highlighted, with a focus on key unanswered questions and with implications for improving the understanding of cancer pathogenesis and developing innovative cancer management strategies.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 17Accelerating Drug Development Using Spatial Multi-omics - 4 day(s) ago
Summary:. Spatial biology approaches enabled by innovations in imaging biomarker platforms and artificial intelligence–enabled data integration and analysis provide an assessment of patient and disease heterogeneity at ever-increasing resolution. The utility of spatial biology data in accelerating drug programs, however, requires balancing exploratory discovery investigations against scalable and clinically applicable spatial biomarker analysis.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 15
Summary:. Liquid biopsies are emerging as powerful minimally invasive approaches that have the potential to solve several long-standing problems spanning the continuum of cancer care: early detection of cancer, minimal residual disease tracking, and refinement of the heterogeneity of clinical responses together with therapeutic response monitoring in the metastatic setting. Existing challenges driven by technical limitations and establishment of the clinical value of liquid biopsies represent fields of active research that call for convergence science approaches to bridge scientific discovery with clinical care.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 55Cell States in Cancer: Drivers, Passengers, and Trailers - 6 day(s) ago
Summary:. Cancer is traditionally perceived through a genetic lens, with therapeutic strategies targeting oncogenic driver mutations. We advocate an overarching framework recognizing tumors as comprising driver, passenger, and trailer cell states: Tailoring therapies to simultaneously target driver genetics and cell states may enhance effectiveness and durability.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0CD News | American Association for Cancer Research - 6 day(s) ago
MyProstateScore 2.0 (MPS2) proved more accurate at detecting prostate cancer than PSA and other biomarkers, researchers reported, sparing men more invasive testing, such as prostate biopsies and MRI (JAMA Oncol 2024 Apr 18). The test was designed to specifically identify higher-grade disease by measuring expression of 18 genes most often found in the presence of significant cancers. In 743 men with elevated PSA levels, using MPS2 would have avoided 35% to 42% of prostate biopsies without missing diagnoses
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Alectinib OK’d for NSCLC - 6 day(s) ago
Genentech’s alectinib (Alecensa) received FDA approval for adjuvant treatment of non–small cell lung cancer (NSCLC) in patients with ALK-positive disease. The decision was based on the phase III ALINA trial, in which 257 patients with stage IB to IIIA NSCLC received either alectinib or platinum-based chemotherapy following surgery (N Engl J Med 2024;390:1265–76). Researchers reported that median disease-free survival (DFS) among patients with stage II to IIIA disease who received the ALK inhibitor was not reached, whereas median DFS was 44.4 months among those who received chemotherapy. In the overall study population, median DFS was not reached with alectinib and was 41.3 months with chemotherapy.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 18Advancing Cancer Interception - 6 day(s) ago
Summary:. Rapid advances in technology and therapeutics, along with better methods to discern who is at risk for cancer by genetic testing and other means, has enabled the development of cancer interception. Targeted therapies and “immuno-interception” may eliminate premalignant lesions and require clinical trial and treatment paradigms altogether distinct from current approaches.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5
Read the paper: https://doi.org/10.1158/2159-8290.CD-23-1441
Source: vimeo.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Investigational Urine Test Better at Finding Prostate Cancer - 6 day(s) ago
MyProstateScore 2.0 (MPS2) proved more accurate at detecting prostate cancer than PSA and other biomarkers, researchers reported, sparing men more invasive testing, such as prostate biopsies and MRI (JAMA Oncol 2024 Apr 18). The test was designed to specifically identify higher-grade disease by measuring expression of 18 genes most often found in the presence of significant cancers. In 743 men with elevated PSA levels, using MPS2 would have avoided 35% to 42% of prostate biopsies without missing diagnoses of clinically significant disease, whereas existing biomarker testing could have avoided only 15% to 30% of biopsies. The improvement was more dramatic in men who previously had negative biopsies—the rate of unnecessary biopsies dropped to between 46% to 51% compared with 9% to 21% for existing tests. One limitation of the trial, however, was that only 13% of participants were African American, a population known to have a higher prevalence of prostate cancer.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet
Read a Special Commentary from the April issue— Targeting Senescence for Next-Generation Cancer Treatments, by Eric Gilson, Pierre Soubeyran, and Eric Solary. https://t.co/qeRxoZshhI @BRIC_Bordeaux @Univ_CotedAzur @CNRS @Inserm @UnivParisSaclay https://t.co/YCbObNSwfg